

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05382 A1

(51) International Patent Classification⁷: A61K 31/00 (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/EP00/06545 (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 10 July 2000 (10.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9916882.5 19 July 1999 (19.07.1999) GB

(71) Applicant (*for all designated States except US*): PHARMACIA & UPJOHN SPA [IT/IT]; Via Robert Koch, 1.2, I-20152 Milan (IT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): GERONI, Maria, Cristina [IT/IT]; Via Correggio, 48, I-20149 Milan (IT). RIPAMONTI, Marina [IT/IT]; V.le Fulvio Testi, 91, I-20162 Milan (IT). CARUSO, Michele [IT/IT]; Via Desiderio, 3, I-20131 Milan (IT). SUARATO, Antonino [IT/IT]; Via Degli Imbriani, 39, I-20158 Milan (IT).

Published:

- *With international search report.*
- *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SYNERGISTIC COMPOSITION COMPRISING DAUNORUBICIN DERIVATIVES AND ANTIMETABOLITE COMPOUNDS

(57) Abstract: The combined use of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methansulfonyl daunorubicin or 4-demethoxy-N,N-bis(2-chloroethyl)-4'-methansulfonyl daunorubicin and an antimetabolite compound in the treatment of tumors, especially in the treatment or prevention of metastasis or in the treatment of tumors by the inhibition of angiogenesis.

WO 01/05382 A1



2001012515001